Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Eiji Iwama, K. Sakai, K. Azuma, T. Harada, D. Harada, K. Nosaki, K. Hotta, F. Ohyanagi, T. Kurata, T. Fukuhara, H. Akamatsu, K. Goto, T. Shimose, Junji Kishimoto, Yoichi Nakanishi, K. Nishio, Isamu Okamoto

研究成果: ジャーナルへの寄稿記事

23 引用 (Scopus)

抄録

Background: Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) during treatment of patients with the epidermal growth factor receptor (EGFR) inhibitor afatinib. Patients and methods: Eligible patients had advanced lung adenocarcinoma with EGFR activating mutations and were treated with afatinib. Plasma samples were collected before and during (4 and 24 weeks) afatinib treatment as well as at disease progression. Tumor and plasma DNA were analyzed by dPCR and NGS. Results: Thirty-five patients were enrolled. The objective response rate and median progression-free survival (PFS) were 77.1% and 13.8 months, respectively. Tumor and plasma DNA were available for 32 patients. dPCR and NGS detected EGFR activating mutations in 81.3% and 71.9% of baseline cfDNA samples, respectively. In 19 patients treated with afatinib for≥24 weeks, the number of EGFR mutant alleles detected in cfDNA by dPCR declined rapidly and markedly after treatment onset, becoming undetectable or detectable at only a low copy number ( < 10 copies per milliliter) at 4 weeks. Median PFS was slightly longer for patients with undetectable EGFR mutant alleles in cfDNA at 4 weeks than for those in whom such alleles were detectable (14.3 versus 10.0 months). A total of 45 somatic mutations was identified in baseline tumor DNA, and 30 (66.7%) of these mutations were identified in cfDNA by NGS. Allele frequency for somatic mutations in cfDNA determined by NGS changed concordantly during afatinib treatment with the number of EGFR mutant alleles determined by dPCR. Conclusions: Monitoring of cfDNA by dPCR is informative for prediction of afatinib efficacy, whereas that by NGS is reliable and has the potential to identify mechanisms of treatment resistance.

元の言語英語
ページ(範囲)136-141
ページ数6
ジャーナルAnnals of Oncology
28
発行部数1
DOI
出版物ステータス出版済み - 1 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Polymerase Chain Reaction
Mutation
DNA
Alleles
DNA-Directed DNA Polymerase
Therapeutics
Disease-Free Survival
Neoplasms
Adenocarcinoma of lung
BIBW 2992
Gene Frequency
Disease Progression
Biopsy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

これを引用

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. / Iwama, Eiji; Sakai, K.; Azuma, K.; Harada, T.; Harada, D.; Nosaki, K.; Hotta, K.; Ohyanagi, F.; Kurata, T.; Fukuhara, T.; Akamatsu, H.; Goto, K.; Shimose, T.; Kishimoto, Junji; Nakanishi, Yoichi; Nishio, K.; Okamoto, Isamu.

:: Annals of Oncology, 巻 28, 番号 1, 01.01.2017, p. 136-141.

研究成果: ジャーナルへの寄稿記事

Iwama, E, Sakai, K, Azuma, K, Harada, T, Harada, D, Nosaki, K, Hotta, K, Ohyanagi, F, Kurata, T, Fukuhara, T, Akamatsu, H, Goto, K, Shimose, T, Kishimoto, J, Nakanishi, Y, Nishio, K & Okamoto, I 2017, 'Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations', Annals of Oncology, 巻. 28, 番号 1, pp. 136-141. https://doi.org/10.1093/annonc/mdw531
Iwama, Eiji ; Sakai, K. ; Azuma, K. ; Harada, T. ; Harada, D. ; Nosaki, K. ; Hotta, K. ; Ohyanagi, F. ; Kurata, T. ; Fukuhara, T. ; Akamatsu, H. ; Goto, K. ; Shimose, T. ; Kishimoto, Junji ; Nakanishi, Yoichi ; Nishio, K. ; Okamoto, Isamu. / Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. :: Annals of Oncology. 2017 ; 巻 28, 番号 1. pp. 136-141.
@article{491739bf1cfa43888d645af20227feba,
title = "Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations",
abstract = "Background: Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) during treatment of patients with the epidermal growth factor receptor (EGFR) inhibitor afatinib. Patients and methods: Eligible patients had advanced lung adenocarcinoma with EGFR activating mutations and were treated with afatinib. Plasma samples were collected before and during (4 and 24 weeks) afatinib treatment as well as at disease progression. Tumor and plasma DNA were analyzed by dPCR and NGS. Results: Thirty-five patients were enrolled. The objective response rate and median progression-free survival (PFS) were 77.1{\%} and 13.8 months, respectively. Tumor and plasma DNA were available for 32 patients. dPCR and NGS detected EGFR activating mutations in 81.3{\%} and 71.9{\%} of baseline cfDNA samples, respectively. In 19 patients treated with afatinib for≥24 weeks, the number of EGFR mutant alleles detected in cfDNA by dPCR declined rapidly and markedly after treatment onset, becoming undetectable or detectable at only a low copy number ( < 10 copies per milliliter) at 4 weeks. Median PFS was slightly longer for patients with undetectable EGFR mutant alleles in cfDNA at 4 weeks than for those in whom such alleles were detectable (14.3 versus 10.0 months). A total of 45 somatic mutations was identified in baseline tumor DNA, and 30 (66.7{\%}) of these mutations were identified in cfDNA by NGS. Allele frequency for somatic mutations in cfDNA determined by NGS changed concordantly during afatinib treatment with the number of EGFR mutant alleles determined by dPCR. Conclusions: Monitoring of cfDNA by dPCR is informative for prediction of afatinib efficacy, whereas that by NGS is reliable and has the potential to identify mechanisms of treatment resistance.",
author = "Eiji Iwama and K. Sakai and K. Azuma and T. Harada and D. Harada and K. Nosaki and K. Hotta and F. Ohyanagi and T. Kurata and T. Fukuhara and H. Akamatsu and K. Goto and T. Shimose and Junji Kishimoto and Yoichi Nakanishi and K. Nishio and Isamu Okamoto",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/annonc/mdw531",
language = "English",
volume = "28",
pages = "136--141",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

AU - Iwama, Eiji

AU - Sakai, K.

AU - Azuma, K.

AU - Harada, T.

AU - Harada, D.

AU - Nosaki, K.

AU - Hotta, K.

AU - Ohyanagi, F.

AU - Kurata, T.

AU - Fukuhara, T.

AU - Akamatsu, H.

AU - Goto, K.

AU - Shimose, T.

AU - Kishimoto, Junji

AU - Nakanishi, Yoichi

AU - Nishio, K.

AU - Okamoto, Isamu

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) during treatment of patients with the epidermal growth factor receptor (EGFR) inhibitor afatinib. Patients and methods: Eligible patients had advanced lung adenocarcinoma with EGFR activating mutations and were treated with afatinib. Plasma samples were collected before and during (4 and 24 weeks) afatinib treatment as well as at disease progression. Tumor and plasma DNA were analyzed by dPCR and NGS. Results: Thirty-five patients were enrolled. The objective response rate and median progression-free survival (PFS) were 77.1% and 13.8 months, respectively. Tumor and plasma DNA were available for 32 patients. dPCR and NGS detected EGFR activating mutations in 81.3% and 71.9% of baseline cfDNA samples, respectively. In 19 patients treated with afatinib for≥24 weeks, the number of EGFR mutant alleles detected in cfDNA by dPCR declined rapidly and markedly after treatment onset, becoming undetectable or detectable at only a low copy number ( < 10 copies per milliliter) at 4 weeks. Median PFS was slightly longer for patients with undetectable EGFR mutant alleles in cfDNA at 4 weeks than for those in whom such alleles were detectable (14.3 versus 10.0 months). A total of 45 somatic mutations was identified in baseline tumor DNA, and 30 (66.7%) of these mutations were identified in cfDNA by NGS. Allele frequency for somatic mutations in cfDNA determined by NGS changed concordantly during afatinib treatment with the number of EGFR mutant alleles determined by dPCR. Conclusions: Monitoring of cfDNA by dPCR is informative for prediction of afatinib efficacy, whereas that by NGS is reliable and has the potential to identify mechanisms of treatment resistance.

AB - Background: Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) during treatment of patients with the epidermal growth factor receptor (EGFR) inhibitor afatinib. Patients and methods: Eligible patients had advanced lung adenocarcinoma with EGFR activating mutations and were treated with afatinib. Plasma samples were collected before and during (4 and 24 weeks) afatinib treatment as well as at disease progression. Tumor and plasma DNA were analyzed by dPCR and NGS. Results: Thirty-five patients were enrolled. The objective response rate and median progression-free survival (PFS) were 77.1% and 13.8 months, respectively. Tumor and plasma DNA were available for 32 patients. dPCR and NGS detected EGFR activating mutations in 81.3% and 71.9% of baseline cfDNA samples, respectively. In 19 patients treated with afatinib for≥24 weeks, the number of EGFR mutant alleles detected in cfDNA by dPCR declined rapidly and markedly after treatment onset, becoming undetectable or detectable at only a low copy number ( < 10 copies per milliliter) at 4 weeks. Median PFS was slightly longer for patients with undetectable EGFR mutant alleles in cfDNA at 4 weeks than for those in whom such alleles were detectable (14.3 versus 10.0 months). A total of 45 somatic mutations was identified in baseline tumor DNA, and 30 (66.7%) of these mutations were identified in cfDNA by NGS. Allele frequency for somatic mutations in cfDNA determined by NGS changed concordantly during afatinib treatment with the number of EGFR mutant alleles determined by dPCR. Conclusions: Monitoring of cfDNA by dPCR is informative for prediction of afatinib efficacy, whereas that by NGS is reliable and has the potential to identify mechanisms of treatment resistance.

UR - http://www.scopus.com/inward/record.url?scp=85015734701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015734701&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw531

DO - 10.1093/annonc/mdw531

M3 - Article

C2 - 28177428

AN - SCOPUS:85015734701

VL - 28

SP - 136

EP - 141

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -